石山醇通过AMPK依赖的机制减轻了OxLDL诱导的内皮功能障碍
Tsan-Hung Chiu1, Chang-Wen Ku2,3, Tsung-Jung Ho2,3,4
1Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung, Taiwan.
The American journal of Chinese medicine
|July 30, 2023
概括
石松醇 (SAL) 通过激活AMPK和抑制ROS生成来保护氧化LDL诱导的内皮细胞损伤. 这项研究揭示了SAL SAL.
科学领域:
- 心血管科学 心血管科学
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 动脉样硬化是导致死亡的主要原因,涉及由氧化低密度脂蛋白 (oxLDL) 驱动的纤维脂肪病变.
- 抗氧化剂食补充剂在预防神经动脉疾病方面表现有前途.
- 石松醇 (SAL) 减弱了内皮细胞中oxLDL诱导的亡和反应性氧物种 (ROS),但机制尚不清楚.
研究的目的:
- 阐明石松 (SAL) 对抗oxLDL诱导的内皮细胞损伤产生心血管保护作用的分子机制.
- 调查腺单酸盐激活蛋白激酶 (AMPK),蛋白激酶C (PKC) 和ROS在SAL的保护作用中的作用.
主要方法:
- 人类静脉内皮细胞 (HUVEC) 用SAL和oxLDL进行治疗.
- 测量了AMPK酸化,PKC酸化和ROS生成.
- 使用AMPK淘汰,siRNA和药理学抑制剂/激活剂 (AICAR,Gö 6983,DPI) 证实了效果.
- 评估了线粒体功能,亡标志物 (Bcl-2/Bax比,细胞染色体c释放) 和caspase-3激活.
主要成果:
- 盐酸以时间和剂量依赖的方式增强了AMPK酸化.
- 沙尔逆转了oxLDL诱导的AMPK脱化和PKC化.
- SAL抑制了oxLDL诱导的NADPH氧化酶组合和ROS生成.
- 盐酸抑制了oxLDL诱导的细胞内的升高,线粒体膜潜在的崩,降低了Bcl-2/Bax比率,cytochrome c的释放,和caspase-3的激活.
结论:
- 盐酸激活AMPK,它对其对抗oxLDL诱导的内皮细胞损伤的保护作用起着至关重要的作用.
- 盐酸通过调节AMPK/PKC/ROS通路和线粒体完整性来减轻氧化应激和亡.
- 这些发现为SAL作为预防动脉样硬化的治疗剂的潜力提供了机械洞察力.
相关概念视频
cAMP-dependent Protein Kinase Pathways
6.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463


